5M4V

X-ray structure of the mambaquaretin-1, a selective antagonist of the vasopressin type 2 receptor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.06 Å
  • R-Value Free: 0.156 
  • R-Value Work: 0.131 
  • R-Value Observed: 0.132 

wwPDB Validation   3D Report Full Report


This is version 1.3 of the entry. See complete history


Literature

Green mamba peptide targets type-2 vasopressin receptor against polycystic kidney disease.

Ciolek, J.Reinfrank, H.Quinton, L.Viengchareun, S.Stura, E.A.Vera, L.Sigismeau, S.Mouillac, B.Orcel, H.Peigneur, S.Tytgat, J.Droctove, L.Beau, F.Nevoux, J.Lombes, M.Mourier, G.De Pauw, E.Servent, D.Mendre, C.Witzgall, R.Gilles, N.

(2017) Proc Natl Acad Sci U S A 114: 7154-7159

  • DOI: https://doi.org/10.1073/pnas.1620454114
  • Primary Citation of Related Structures:  
    5M4V

  • PubMed Abstract: 

    Polycystic kidney diseases (PKDs) are genetic disorders that can cause renal failure and death in children and adults. Lowering cAMP in cystic tissues through the inhibition of the type-2 vasopressin receptor (V2R) constitutes a validated strategy to reduce disease progression. We identified a peptide from green mamba venom that exhibits nanomolar affinity for the V2R without any activity on 155 other G-protein-coupled receptors or on 15 ionic channels. Mambaquaretin-1 is a full antagonist of the V2R activation pathways studied: cAMP production, beta-arrestin interaction, and MAP kinase activity. This peptide adopts the Kunitz fold known to mostly act on potassium channels and serine proteases. Mambaquaretin-1 interacts selectively with the V2R through its first loop, in the same manner that aprotinin inhibits trypsin. Injected in mice, mambaquaretin-1 increases in a dose-dependent manner urine outflow with concomitant reduction of urine osmolality, indicating a purely aquaretic effect associated with the in vivo blockade of V2R. CD1-pcy/pcy mice, a juvenile model of PKD, daily treated with 13 [Formula: see text]g of mambaquaretin-1 for 99 d, developed less abundant (by 33%) and smaller (by 47%) cysts than control mice. Neither tachyphylaxis nor apparent toxicity has been noted. Mambaquaretin-1 represents a promising therapeutic agent against PKDs.


  • Organizational Affiliation

    Service d'Ingénierie Moléculaire des Protéines, Institut des Sciences du Vivant Frédéric Joliot, Commissariat à l'Energie Atomique, Université Paris-Saclay, F-91191 Gif sur Yvette, France.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Mambaquaretin-157Dendroaspis angusticepsMutation(s): 0 
UniProt
Find proteins for A0A1Z0YU59 (Dendroaspis angusticeps)
Explore A0A1Z0YU59 
Go to UniProtKB:  A0A1Z0YU59
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupA0A1Z0YU59
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.06 Å
  • R-Value Free: 0.156 
  • R-Value Work: 0.131 
  • R-Value Observed: 0.132 
  • Space Group: P 4 21 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 63.84α = 90
b = 63.84β = 90
c = 32.96γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
XDSdata reduction
XSCALEdata scaling
PHASERphasing
Cootmodel building

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2017-05-03
    Type: Initial release
  • Version 1.1: 2017-06-28
    Changes: Database references
  • Version 1.2: 2017-07-12
    Changes: Database references
  • Version 1.3: 2024-01-17
    Changes: Data collection, Database references, Refinement description